Ignite Creation Date:
2024-05-05 @ 5:09 PM
Last Modification Date:
2024-10-26 @ 9:28 AM
Study NCT ID:
NCT00395733
Status:
COMPLETED
Last Update Posted:
2013-12-18
First Post:
2006-11-02
Brief Title:
Efficacy and Safety Study to Evaluate Gadavist Gadobutrol as Contrast Agent in Magnetic Resonance Imaging MRI of Vascular Diseases in Chinese Patients
Sponsor:
Bayer
Organization:
Bayer
Study Overview
Official Title:
A Single-blind Intra-individual Crossover Multicenter Study of the Efficacy Safety and Tolerability of Gadavist 10 M in Comparison With Magnevist 05 M as Contrast Agent in the Enhanced Magnetic Resonance Angiography MRA in Chinese Patients
Status:
COMPLETED
Status Verified Date:
2013-11
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to determine if the contrast agent is effective and safe in the Magnetic Resonance Imaging MRI of vascular diseases in patients of Chinese origin
Detailed Description:
The study has previously been posted by Schering AG Germany Schering AG Germany has been renamed to Bayer HealthCare AG Germany Bayer HealthCare AG Germany is the sponsor of the trial
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 309762 | OTHER | Company internal | None |